Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] Administration. Losmapimod is currently in a Phase 2 clinical trial for facioscapulohumeral muscular dystrophy ( FSHD). The drug qualified for this status because FSHD, with an estimated 20-40,000 affected individuals […]
[…] safe. Join us on Thursday, March 26, at 1:00 PM ET, for our next live FSHD Society Sequester Camp webinar on “Ways to Connect. Ways to Help.” Please know that […]
[…] Voice of the Patient Forum (or patient-focused drug development meeting) for facioscapulohumeral muscular dystrophy ( FSHD) that is being organized by the FSHD Society for April 21. James Valentine explains […]
[…] approach to treating facioscapulohumeral muscular dystrophy. She describes the company’s scientific research to develop “ FSHD in a dish” models to screen and identify candidate drugs that can suppress the […]
This year, the FSHD Society – empowered by you – launched an aggressive plan to accelerate therapeutic development for FSHD. We brought together pharmaceutical companies, researchers, government agencies, and families […]
